Patients who have experienced Post-Transplant CMV: We Need Your Help!
Lymphoma Canada, along with an alliance of other blood cancer organizations, is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Quebec equivalent Institut national d’excellence en santé et services sociaux (INESSS) for an upcoming drug review on Maribavir for the treatment of transplant recipients with refractory, with or without resistance (R/R), cytomegalovirus (CMV).
Transplant patients are among those most vulnerable to a CMV infection, especially in the critical few months after the transplant. For most people with healthy immune systems, CMV is a quiet invader that causes no symptoms. Patients can live their entire lives completely unaware they have the virus. But when the immune system weakens, this normally dormant virus can re-awaken with life-threatening potential. After the transplant, when patients are immunosuppressed or taking immunosuppressive therapies, your immune system’s function is reduced which means that the CMV virus is more likely to multiply and become symptomatic. Without treatment, CMV can cause serious complications and health concerns.
If you have/had CMV post stem-cell transplant, and have received Maribavir as a treatment, you can help by completing our survey. You can still participate in this survey if you have had CMV but have not received this treatment. This survey provides us with valuable patient input about CMV and its treatment for this submission. CADTH and INESSS use this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on February 28, 2022, and should only take between 10-15 minutes of your time.